Bayer AG

BAYN

DE000BAY0017

Pharmaceuticals

Market Closed - Xetra Other stock markets 16:39:28 15/01/2026 GMT			5-day change	1st Jan Change
42.10 ^EUR	+1.02%		+6.48%	+13.74%

01-15	Bayer Upgraded to Buy as mwb Notes 'Improving Medium-term Risk-Reward'	MT
01-15	European Midday Briefing : Shares Rise; Gold and Oil Fall on Easing U.S.-Iran Tensions	DJ

BAYER AG : Goldman Sachs remains its Buy rating

Published on 12/02/2025 at 08:03 am GMT

MarketScreener with dpa-AFX Analyser

Bayer AG

+1.02%

James Quigley from Goldman Sachs retains his positive opinion on the stock with a Buy rating. The target price continues to be set at EUR 38.50.

Latest news about Bayer AG

01-15	Bayer Upgraded to Buy as mwb Notes 'Improving Medium-term Risk-Reward'	MT
01-15	European Midday Briefing : Shares Rise; Gold and Oil Fall on Easing U.S.-Iran Tensions	DJ
01-14	German DAX Index Slips; Bayer, RWE Shares Surge	MT
01-14	Frankfurt Stocks Close: DAX Ends Impressive Record-Breaking Streak	DP
01-14	Orion Sees Long-Term Nubeqa Sales Surpassing 1 Billion Euros – Issues 2026 Forecast (Update)	FW
01-14	Orion Estimates to Hit Annual Net Sales Target for Nubeqa by Decade-end	MT
01-14	Bayer Shares Surge as Partner Forecasts Sales Growth for Prostate-Cancer Drug	DJ
01-14	Bayer Continues Recovery Rally – Sees Major Pharma Potential Ahead	DP
01-14	Ipsen and EMS-Chemie Shine on the Stock Market, Vistry and Pearson Struggle
01-14	Bayer Sees Pharmaceutical Business on Growth Trajectory	DP
01-14	U.S. Futures Fall, Precious Metals Gain on Iranian Unrest	DJ
01-14	Historic Morning Record for the CAC 40
01-14	Bayer Targets Around 30 Percent Margin for Pharma Division by 2030	RE
01-14	Orion Sees Long-Term Nubeqa Sales Surpassing 1 Billion Euros – Issues 2026 Forecast	FW
01-13	Bayer targets return to mid-single-digit pharma growth by 2027	RE
01-13	Bayer Aktiengesellschaft Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 11:15 AM
01-12	Bayer acquires two imaging markers currently in development from Attralus, Inc	RE
01-10	FluroTech Ltd. Announces Chief Financial Officer Changes	CI
01-08	Askbio Inc. Announces Fda Acceptance of Investigational New Drug Application for Ab-1009 Gene Therapy for Treatment of Late-Onset Pompe Disease	CI
01-08	Bayer Shares Climb Further on EU Seed Policy Report	DP
01-08	FDA accepts AskBio investigational new drug for late-onset Pompe disease	RE
01-08	Drugmakers brace for Europe pricing fight after Trump's US price-cut deals	RE
01-08	Bayer Approaches Recent Highs - Report on EU Seed Policy	DP
01-08	Bayer Partners with Soufflé Therapeutics to Develop siRNA Therapy for Rare Heart Disease	MT
01-08	Bayer and Souffle Therapeutics Announce Strategic Collaboration to Advance Cell-Specific Heart-Targeted siRNA Therapy	CI

Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (47.8%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (38.9%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.6%); - other (0.7%). Net sales are distributed geographically as follows: Germany (5.2%), Switzerland (1.2%), Europe/Middle East/Africa (23.6%), the United States (31.7%), North America (3.6%), China (7.7%), Asia/Pacific (9.6%), Brazil (9.3%) and Latin America (8.1%).

Employees

88,502

Sector

Pharmaceuticals

Calendar

01-18 - Kepler Cheuvreux German Corporate Conference

More about the company